Interview with Michele Garot, Vice President, BeCRO
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Address: Sint lambertusstraat 141 Rue Saint LambertB- 1200 Brussels,Belgium
Tel:
Web: http://www.becro.be/
BeCRO is the Belgian Association of CRO’s. BeCRO was initially founded by 19 member companies and has now grown to include 32 active members, representing more than a third of the 83 identified CRO’s in the country in 2011.
The aims of BeCRO are:
– To establish an association of service and consultancy companies active in pharmaceutical and medical development for health products, companies involved in the running of complete preclinical or clinical trials or parts thereof,- To represent and defend the interests of such companies to health authorities, companies, institutions and organisations operating in the health sector,- To be recognised as a privileged interlocutor by health authorities, any professional bodies and any national or international association and/or federation,- To establish good operating practices, with respect as regards highest quality rules and Good Clinical Practices,- To work towards training its members,- To promote the association.
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without…
Joris Van Assche, managing director of the Belgian association for accessible medicines, Medaxes, highlights the need for a stronger policy to create a more positive environment for generic and biosimilar…
Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder…
After reaching revenues of EUR 2.323 billion in the first six months of 2019, UCB announced on December 18 that it will build an innovative multi-product biological manufacturing facility on…
The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC),…
Jean-Christophe Tellier became UCB’s CEO on January 1, 2015 only a few years joining the company in 2011. Before taking on the role Tellier held positions as executive VP of…
Annie Hubert, Senior Director, EU Section & Public Policy for the Alliance for Regenerative Medicine (ARM) describes some of the issues that companies in the advanced therapies field are facing…
One of NNE Pharmaplan’s latest exciting news is that last year you established offices to accommodate your existing customers in Belgium. What were the strategic motivations for establishing a presence…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mr. Heyman, you inherited the chair and management of Janssen Pharmaceutica. What core values and spirit of Dr. Paul Janssen were you asked by the Janssen family to perpetuate throughout…
Mrs van der Kamp, you launched your career as a strategy consultant however, since then you have moved into the pharmaceutical industry by joining Novartis where you quickly worked your…
With an expenditure of more than 10% of GDP on health, Belgium maintains one of the world’s leading healthcare systems. That said, could you please comment on the current state…
See our Cookie Privacy Policy Here
